The generic name of Class K is Infliximab for Injection, and the time needed for patients with Crohn’s disease to be treated with Infliximab varies depending on the individual’s constitution and condition, and may take 1 to 2 years or 4 to 5 years. Infliximab for injection is a human-mouse chimeric monoclonal antibody to TNFα, which binds to TNFα and blocks its binding to the receptor, thereby inhibiting its action and suppressing the development of inflammation. It is commonly used in the clinic for the treatment of rheumatoid arthritis, Crohn’s disease, ankylosing spondylitis, psoriasis, ulcerative colitis and other diseases. In the treatment of Crohn’s disease, Infliximab for Injection usually takes 1~2 years to reach remission, but due to the differences in individual constitution and condition, some patients may take 4~5 years to enter remission. Infliximab for injection may have adverse reactions such as upper respiratory tract infection, abdominal pain and distension, nausea, abnormal liver function, sepsis, etc. It should be contraindicated for patients suffering from tuberculosis or other active infections (e.g., sepsis, abscess, etc.), patients with moderate-to-severe heart failure, and pregnant women and nursing mothers. The medication should be taken in strict accordance with the doctor’s instructions, and should not be used on its own, so as not to delay or even aggravate the condition.